Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia 10Breast Neoplasms 10Prostatic Neoplasms 8Lymphoma, Follicular 8Lymphoma 8Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Adenocarcinoma of Lung 5Rectal Neoplasms 4Multiple Myeloma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Kidney Neoplasms 4Hodgkin Disease 4Congenital Abnormalities 4Colorectal Neoplasms 4Colonic Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Neoplasms, Plasma Cell 3Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Extranodal NK-T-Cell 3Leukemia, Myeloid, Acute 3Burkitt Lymphoma 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

fludarabine phosphate 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Cyclosporine 2ruxolitinib 1merphos 1Tacrolimus 1Methotrexate 1MK 2206 1In Situ Hybridization, Fluorescence 1Flow Cytometry 1Cytogenetic Analysis 1Cyclophosphamide 1Busulfan 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myeloproliferative Syndrome, Transient × Amplified Fragment Length Polymorphism Analysis × Clear all
NCT00322101 2014-10-31

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Fred Hutchinson Cancer Center

Phase 3 Completed
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Chromosome 5q Deletion Syndrome, Myeloproliferative Syndrome, Transient, Congenital Abnormalities, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡